Company intelligence / Profile preview

OpenCell Technologies

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

OpenCell Technologies has developed a proprietary continuous and scalable non-viral transfection technology called Softporation™, which enables efficient delivery of large cargos into challenging cell types. This platform is designed to enhance the effectiveness and scalability of cellular engineering for biopharma and cell & gene therapy applications. There are currently no active clinical trials sponsored by the company.

Therapeutic areas: Other
Modalities: Cell therapiesGene therapies
Industry: Non-Drug Biotech

Partnerships

Adva Biotechnology – strategic partnership to integrate Opencell’s Softporation™ technology with Adva’s automated manufacturing platforms for advanced cell therapies

Beyond the preview

Go deeper on OpenCell Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OpenCell Technologies.

Explore the full profile